Predicting ligand-dependent tumors from multi-dimensional signaling features

por Hass, Helge, Masson, Kristina, Wohlgemuth, Sibylle, Paragas, Violette, Allen, John E., Sevecka, Mark, Pace, Emily, Timmer, Jens, Stelling, Joerg, MacBeath, Gavin, Schoeberl, Birgit, Raue, Andreas
Publicado 2017

A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells

por Weïwer, Michel, Spoonamore, James, Wei, Jingqiang, Guichard, Boris, Ross, Nathan T., Masson, Kristina, Silkworth, Whitney, Dandapani, Sivaraman, Palmer, Michelle, Scherer, Christina A., Stern, Andrew M., Schreiber, Stuart L., Munoz, Benito
Publicado 2012

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

por Emdal, Kristina B., Palacio-Escat, Nicolàs, Wigerup, Caroline, Eguchi, Akihiro, Nilsson, Helén, Bekker-Jensen, Dorte B., Rönnstrand, Lars, Kazi, Julhash U., Puissant, Alexandre, Itzykson, Raphaël, Saez-Rodriguez, Julio, Masson, Kristina, Blume-Jensen, Peter, Olsen, Jesper V.
Publicado 2022

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)

por Schoeberl, Birgit, Kudla, Art, Masson, Kristina, Kalra, Ashish, Curley, Michael, Finn, Gregory, Pace, Emily, Harms, Brian, Kim, Jaeyeon, Kearns, Jeff, Fulgham, Aaron, Burenkova, Olga, Grantcharova, Viara, Yarar, Defne, Paragas, Violette, Fitzgerald, Jonathan, Wainszelbaum, Marisa, West, Kip, Mathews, Sara, Nering, Rachel, Adiwijaya, Bambang, Garcia, Gabriela, Kubasek, Bill, Moyo, Victor, Czibere, Akos, Nielsen, Ulrik B, MacBeath, Gavin
Publicado 2017